CorMedix Reports Strong Q1 Revenue Growth, Raises Full-Year Guidance
CorMedix (NASDAQ:CRMD) reported first-quarter revenue of $127.4 million, a 226% increase year-over-year and above analyst estimates. Despite missing EPS expectations slightly at $0.43 per share versus the expected $0.45, shares rose due to strong performance from its DefenCath product line and an upward revision in full-year revenue guidance.
Tickers: $CRMD
Topics: medical_research pharmaceuticals